The market's attempts at gains have been denied in the face of weaker consumer confidence in February than had been expected.

Lilly expands its Zepbound vial offering, as HIMS pulls back on semaglutide, and other biotech news in today's Readout ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Trump DOJ’s Action Against Health Insurance Companies.

Hims stock plunged Tuesday after the compounding pharmacy issued a bullish outlook that still includes knockoff versions of ...

Stock in Hims & Hers Health was bound to tumble once it [could no longer sell]( ...